Azafaros
About
Azafaros is a clinical-stage biotech company developing oral therapies for rare genetic metabolic disorders, including lysosomal diseases. Its lead development strategy focuses on compounds designed to cross the blood-brain barrier and address severe neurological progression in underserved pediatric conditions.
Investors 1
- Forbion Venture Capital · Naarden
Recent news
- Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug 2025-05-13 · Fierce Biotech
- Azafaros secures €132 million in series B financing to advance phase 3 programs 2025-05-13 · Leiden Bio Science Park